PT102022A - Processo para a producao e purificacao de astaloglicoprotetinas adequadas para uso em vacinas e conjunto de materiais de ensaio para detectar a sua presenca - Google Patents

Processo para a producao e purificacao de astaloglicoprotetinas adequadas para uso em vacinas e conjunto de materiais de ensaio para detectar a sua presenca Download PDF

Info

Publication number
PT102022A
PT102022A PT102022A PT10202297A PT102022A PT 102022 A PT102022 A PT 102022A PT 102022 A PT102022 A PT 102022A PT 10202297 A PT10202297 A PT 10202297A PT 102022 A PT102022 A PT 102022A
Authority
PT
Portugal
Prior art keywords
proteins
astaloglicoprotetins
vaccines
purification
detect
Prior art date
Application number
PT102022A
Other languages
English (en)
Other versions
PT102022B (pt
Inventor
Frank Marcus
Barbara A Gervase
Robert O Ralston
Kent B Thudium
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27417050&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT102022(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of PT102022A publication Critical patent/PT102022A/pt
Publication of PT102022B publication Critical patent/PT102022B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT102022A 1990-11-08 1997-06-26 Processo para a producao e purificacao de astaloglicoprotetinas adequadas para uso em vacinas e conjunto de materiais de ensaio para detectar a sua presenca PT102022B (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61196590A 1990-11-08 1990-11-08
US61141990A 1990-11-08 1990-11-08
US75888091A 1991-09-13 1991-09-13

Publications (2)

Publication Number Publication Date
PT102022A true PT102022A (pt) 1999-01-29
PT102022B PT102022B (pt) 2000-12-29

Family

ID=27417050

Family Applications (2)

Application Number Title Priority Date Filing Date
PT99466A PT99466B (pt) 1990-11-08 1991-11-08 Processo para a producao e purificacao de asialoglicoproteinas adequadas para uso em vacinas e conjunto de materiais de ensaio para detectar a sua presenca
PT102022A PT102022B (pt) 1990-11-08 1997-06-26 Processo para a producao e purificacao de astaloglicoprotetinas adequadas para uso em vacinas e conjunto de materiais de ensaio para detectar a sua presenca

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT99466A PT99466B (pt) 1990-11-08 1991-11-08 Processo para a producao e purificacao de asialoglicoproteinas adequadas para uso em vacinas e conjunto de materiais de ensaio para detectar a sua presenca

Country Status (17)

Country Link
EP (2) EP0842947B2 (pt)
JP (8) JPH06504431A (pt)
AT (1) ATE188220T1 (pt)
AU (1) AU668078B2 (pt)
CA (2) CA2203443C (pt)
CZ (1) CZ289006B6 (pt)
DE (1) DE69131882T3 (pt)
DK (2) DK0842947T4 (pt)
ES (1) ES2139591T5 (pt)
FI (1) FI107803B (pt)
GR (1) GR3032771T3 (pt)
HU (2) HUT66063A (pt)
NO (2) NO304380B1 (pt)
PT (2) PT99466B (pt)
RO (1) RO115446B1 (pt)
SK (3) SK285623B6 (pt)
WO (1) WO1992008734A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
JP3158177B2 (ja) * 1991-10-08 2001-04-23 国立感染症研究所長 Ｃ型肝炎診断薬
AU666176B2 (en) * 1992-01-31 1996-02-01 Abbott Laboratories Mammalian expression systems for HCV proteins
UA39944C2 (uk) * 1992-07-07 2001-07-16 Чірон Корпорейшн Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі
JPH08510240A (ja) 1993-05-12 1996-10-29 カイロン コーポレイション Ｃ型肝炎ウイルスｅ２／ｎｓ１領域の保存モチーフ
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5610009A (en) * 1994-01-28 1997-03-11 Abbott Laboratories Mammalian expression systems for hepatitis C virus envelope genes
DK0773957T3 (da) 1994-07-29 2005-10-24 Chiron Corp Udskilt hepatitis C-virus-E1/E2-kompleks opnået fra C-terminalt trunkerede E1- og E2-polypeptider
DE69526636T3 (de) * 1994-07-29 2006-11-23 Innogenetics N.V. Gereinigte hepatitis-c-virus hüllproteine zur diagnostischen und therapeutischen verwendung
AU3241095A (en) * 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
IT1271593B (it) * 1994-11-30 1997-06-04 Sanitaria Scaligera Spa Procedimento ed apparecchiatura per l'immunoadsorbimento specifico di virus hiv, di antigene gp120 e complesso cd4-gp120.
US6127116A (en) 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
FR2744725B1 (fr) * 1996-02-09 1998-04-30 Pasteur Institut Anticorps specifiques des complexes formes par les glycoproteines e1 et e2 du virus de l'hepatite c, procedes de determination de la presence, et d'isolement de ces complexes
US6514731B1 (en) 1996-05-24 2003-02-04 Chiron Corporation Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens
KR100209095B1 (ko) 1996-06-28 1999-07-15 성재갑 C형 간염 바이러스의 프로테아제의 활성을 측정할 수 있는 c형 간염 대체 바이러스, 그 재조합 유전자 및 그 용도
ATE423204T1 (de) 1996-11-08 2009-03-15 Us Gov Health & Human Serv Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln
US7049428B1 (en) 1998-03-04 2006-05-23 Washington University HCV variants
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
WO1998050556A2 (en) 1997-05-06 1998-11-12 Chiron Corporation Intracellular production of hepatitis c e1 and e2 truncated polypeptides
EP0947525A1 (en) 1998-03-27 1999-10-06 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
AU2001290178A1 (en) 2000-08-17 2002-02-25 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US20030232745A1 (en) * 2001-06-26 2003-12-18 Olson William C. Uses of DC-sign and DC-Signr for inhibiting hepatitis C virus infection
US7022323B2 (en) 2001-06-26 2006-04-04 Progenics Pharmaceuticals, Inc. Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
CA2495680A1 (en) * 2002-08-16 2004-02-26 Bertrand Saunier Hepatitis c viral-like particle purification
US7968697B2 (en) 2005-05-25 2011-06-28 Chrontech Pharma Ab Hepatitis C virus non-structural NS3/4A fusion gene
US20090214593A1 (en) 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3886363T3 (de) * 1987-11-18 2004-09-09 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville NANBV-Diagnostika
IL88599A0 (en) * 1987-12-10 1989-07-31 Cell Bio Group Ltd Glycoprotein cell growth modulating materials,their preparation and compositions containing them
HU225068B1 (en) * 1989-03-17 2006-05-29 Chiron Corp Process for producing diagnostics and vaccine of nanbh
KR100206150B1 (ko) * 1990-04-04 1999-07-01 로버트 피. 블랙버언 항-에이치씨브이 항체에 대한 면역분석용 씨형 간염 바이러스(에이치디브이)항원의 조합체

Also Published As

Publication number Publication date
SK285623B6 (sk) 2007-05-03
SK69097A3 (en) 1997-11-05
DK0842947T4 (da) 2009-06-08
NO972213L (no) 1997-05-14
NO304380B1 (no) 1998-12-07
DK0556292T4 (da) 2006-12-27
JP4056306B2 (ja) 2008-03-05
EP0556292B1 (en) 1999-12-29
FI932025A0 (fi) 1993-05-05
DK0556292T3 (da) 2000-04-17
CZ289006B6 (cs) 2001-10-17
AU9026791A (en) 1992-06-11
ATE188220T1 (de) 2000-01-15
NO304381B1 (no) 1998-12-07
EP0556292B2 (en) 2006-11-29
WO1992008734A1 (en) 1992-05-29
DE69131882T2 (de) 2000-05-04
JP2003093081A (ja) 2003-04-02
SK286106B6 (sk) 2008-03-05
CA2095521A1 (en) 1992-05-09
CA2095521C (en) 2009-06-30
JP2001286290A (ja) 2001-10-16
AU668078B2 (en) 1996-04-26
EP0556292A4 (pt) 1995-01-18
JPH1171395A (ja) 1999-03-16
NO972213D0 (no) 1997-05-14
HU227498B1 (en) 2011-07-28
GR3032771T3 (en) 2000-06-30
JPH06504431A (ja) 1994-05-26
EP0842947B2 (en) 2009-03-18
EP0842947A3 (en) 2001-12-12
PT102022B (pt) 2000-12-29
FI107803B (fi) 2001-10-15
JP2008031181A (ja) 2008-02-14
ES2139591T5 (es) 2007-08-01
JP3207155B2 (ja) 2001-09-10
SK285624B6 (sk) 2007-05-03
CA2203443C (en) 2001-08-28
JP2003174875A (ja) 2003-06-24
PT99466B (pt) 1999-04-30
ES2139591T3 (es) 2000-02-16
FI932025A (fi) 1993-06-07
EP0842947A2 (en) 1998-05-20
NO931680D0 (no) 1993-05-07
RO115446B1 (ro) 2000-02-28
EP0556292A1 (en) 1993-08-25
CZ82493A3 (en) 1994-04-13
DE69131882T3 (de) 2007-05-24
EP0842947B1 (en) 2004-04-21
HU9301336D0 (en) 1993-10-28
HUT66063A (en) 1994-09-28
JP2006219503A (ja) 2006-08-24
JP2005187479A (ja) 2005-07-14
DE69131882D1 (en) 2000-02-03
SK44293A3 (en) 1993-08-11
PT99466A (pt) 1992-10-30
CA2203443A1 (en) 1992-05-09
DK0842947T3 (da) 2004-07-26
NO931680L (no) 1993-06-28

Similar Documents

Publication Publication Date Title
PT102022A (pt) Processo para a producao e purificacao de astaloglicoprotetinas adequadas para uso em vacinas e conjunto de materiais de ensaio para detectar a sua presenca
ATE229543T1 (de) Polypeptide des hepatitis c-virus (hiv)
DE10399037I1 (de) Rekombinante Virusproteine begleitet von lymphadenopathischem Syndrom und/oder "Acquired Immune Deficiency Syndrome" (AIDS)
NZ320276A (en) Method and preparations for stabilizing biological materials by drying methods without freezing
FI893702A0 (fi) Foerfarande foer mikrobiologisk framstaellning av humant serumalbumin och andra heterologa proteiner ur jaest.
DE69535018D1 (de) Papillomavirus vakzine
ATE423204T1 (de) Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln
ES8706208A1 (es) Un metodo para preparar proteinas que son inmunologicamente reactivas con anticuerpos para virus asociados con linfadenopatia
ATE87487T1 (de) Rekombinante hiv-2 polypeptide.
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
RU93043621A (ru) Способы получения гликопротеинов нсv, способ очистки, аналитический набор, способ выявления нсv, способ элиминации нсv, способ индукции иммунитета, гликопротеины, иммунореагенты
EP1471073A3 (en) Hepatitis C virus asialoglycoproteins
FI971702A (fi) Hepatiitti-C-viruksen asialoglykoproteiinit
EP0385394A3 (en) Polyhedrin gene and genetic engineering thereof
KRIVOSHEIN et al. Electrophoretic separation and purification of biological samples in microgravity(Elektroforeticheskoe razdelenie i ochistka biologicheskikh ob'ektov v usloviiakh mikrogravitatsii)
EP0234862A3 (en) Expression of recombinant proteins in yeast

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19970918

FG3A Patent granted, date of granting

Effective date: 20000926

PD4A Change of proprietorship

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC., US

Effective date: 20080215

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20131226